Apogee director granted options on 7,657 shares

Apogee Therapeutics director Mark C. McKenna received a grant of stock options covering 7,657 shares of common stock at an exercise price of $85.00 per share.

Rhea-AI Filing Summary

Apogee Therapeutics director Mark C. McKenna received a grant of stock options covering 7,657 shares of common stock at an exercise price of $85.00 per share. The options vest on the one-year anniversary of the June 9, 2026 grant date, contingent on his continued service, and expire on June 9, 2036.

Insider Trade Summary

Grant/Award: 7,657 shares

Grant/Award 1 txn

Insider McKenna Mark C.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	7,657	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 7,657 contracts (Direct)

Footnotes (1)

1. F1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

Key Figures

Option grant size: 7,657 shares Exercise price: $85.00 per share Total options after grant: 7,657 derivative shares +2 more

5 metrics

Option grant size 7,657 shares Stock options on common stock granted June 9, 2026

Exercise price $85.00 per share Strike price for the 7,657-share option grant

Total options after grant 7,657 derivative shares Total derivative securities following this transaction

Expiration date June 9, 2036 Option term end date for the grant

Vesting schedule 100% after one year Vests on one-year anniversary of grant, with continued service

Key Terms

Stock Option (Right to Buy), exercise price, expiration date, Grant, award, or other acquisition, +1 more

5 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "85.0000""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-06-09T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

continued service financial

"subject to the Reporting Person's continued service to the Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Apogee Therapeutics (APGE) disclose in this Form 4 for Mark C. McKenna?

Apogee Therapeutics reported that director Mark C. McKenna received a grant of stock options for 7,657 shares. These options allow him to buy common stock at $85.00 per share, subject to vesting and other standard conditions over time.

How many Apogee Therapeutics (APGE) shares are covered by McKenna’s new stock options?

The new stock option grant covers 7,657 shares of Apogee Therapeutics common stock. This represents the number of shares he may purchase if he exercises the options once they vest and remain outstanding through their term.

What is the exercise price and expiration date of Mark C. McKenna’s APGE stock options?

The options have an exercise price of $85.00 per share and expire on June 9, 2036. This means McKenna can buy shares at $85.00 any time after vesting and before the June 9, 2036 expiration date, subject to plan terms.

When do Mark C. McKenna’s newly granted Apogee Therapeutics (APGE) options vest?

The options vest on the one-year anniversary of the June 9, 2026 grant date, assuming continued service. If McKenna remains in his role through that date, the full 7,657-share option award will become exercisable as described.

Is Mark C. McKenna’s Apogee Therapeutics (APGE) Form 4 transaction an open-market purchase or a grant?

The Form 4 reflects a grant of stock options, not an open-market purchase. The transaction code "A" indicates a grant or award acquisition, with an exercise price of $85.00 per share and no cash paid at the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/11/2026 - 08:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McKenna Mark C.

(Last) (First) (Middle)

C/O APOGEE THERAPEUTICS, INC.

221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)

WALTHAM MASSACHUSETTS 02453

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$85	06/09/2026		A		7,657		(1)	06/09/2036	Common Stock	7,657	$0.00	7,657	D

Explanation of Responses:

1. This option represents the right to purchase 7,657 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.

	/s/ Matthew Batters, as attorney-in-fact for Mark McKenna	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)